RB1 and cancer: This discrepancy may be attributed to the different methodologies and drug concentrations used in the two studies,19,20 and might impact to a lesser extent when a larger number of heterogeneous pan-cancer cell lines are used, explaining the ability to reveal the correlations between CCNE1, CCNE1/RB1 ratio, and palbociclib IC50 when analyzing the pan-cancer dataset.